IIT-GEORGE-I-PREDICT
Phase I/II
OPEN TO ACCRUAL
An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses
SEAGEN-RC48G001
Phase II
OPEN TO ACCRUAL
A Phase 2 Multi-cohort, Open-label, Multi-center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone and in Combination with Pembrolizumab in Subjects with Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2